If you didn’t get to attend the 2024 ASCO Annual Meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure,” or even if you did (as it’s nearly impossible to consume everything at the event during those four days), here are key highlights from five studies presented at the conference.
The conference featured groundbreaking research and clinical findings that are poised to impact cancer treatment protocols.
Key Takeaways in Oncology Drug Development
Lorlatinib for ALK-Positive NSCLC
- Study: Phase III CROWN
- Findings: Lorlatinib showed unprecedented five-year progression-free survival (PFS) rates for advanced ALK-positive non-small cell lung cancer (NSCLC), significantly outperforming crizotinib. At 60 months, the median PFS was not reached for lorlatinib, compared to 9.1 months for crizotinib. Additionally, lorlatinib demonstrated superior control of brain metastases.
Osimertinib for EGFR-Mutated NSCLC
- Study: LAURA trial
- Findings: Osimertinib improved PFS for patients with unresectable Stage III EGFR-mutated NSCLC, establishing a new standard of care. This therapy is expected to impact overall survival and control of brain metastases significantly.
BrECADD for Hodgkin Lymphoma
- Study: Phase III GHSG HD21
- Findings: BrECADD regimen showed higher effectiveness and fewer side effects compared to BEACOPP in treating Hodgkin lymphoma, with a 94.3% four-year PFS rate. Patients on BrECADD also experienced better fertility outcomes.
Isa-VRd for Multiple Myeloma
- Study: IMROZ study
- Findings: The combination of isatuximab with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) significantly improved PFS and minimal residual disease negativity rates in newly diagnosed multiple myeloma patients not eligible for transplant, suggesting Isa-VRd as a potential new standard of care.
THIO and Checkpoint Inhibitor Combination for NSCLC
- Study: THIO-101
- Findings: The combination of THIO and Libtayo showed an 85% disease control rate in advanced NSCLC patients who had failed multiple standard therapies, indicating a promising new treatment approach.
These studies underscore the progress being made in oncology drug development, offering hope for more effective and personalized cancer treatments.
If you’re launching a new study in the second half of 2024, connect with Medelis to hear our insights about optimal site selection, patient enrollment strategies and operational efficiencies to ensure that our sponsors complete their studies on-time and on-budget.
